Search

everythinglearnresearchcommunity

for

Search:↓

Activating cannabinoid receptor 1 may help manage psoriasis by reducing certain keratins.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Disrupted citric acid metabolism stops hair growth.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Misbehaving hair follicle stem cells can cause hair loss and offer new treatment options.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

The Hr protein binds to DNA, interacts with p53, and affects cell cycle genes.

Androgens block hair growth by disrupting cell signals; targeting GSK-3 may help treat hair loss.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

Drugs like PDEI may help hair disorders like AGA.

Lactate production is important for activating hair growth stem cells.

TCDD changes skin cell growth and keratin production in mice.

Removing STAT5 from 3D-cultured human skin cells reduces their ability to grow hair.

Hedgehog signaling controls hair follicle development and can affect skin cancer growth.

Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.

Certain 4-azasteroids are effective at blocking the enzyme that processes testosterone in human skin and could help treat acne, excessive hair growth, and male pattern baldness.

Different substances affect hair and skin cell growth in various ways, with some promoting and others inhibiting cell proliferation.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

JAK inhibitors show promise for treating skin diseases effectively and safely.

Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.

Targeting impaired Nrf2 signaling might help treat hidradenitis suppurativa early on.

JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.

Removing senescent cells can improve hair growth and regeneration.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.